Evan T Keller

List of Publications by Year
in descending order

267 papers	25,910 citations	9234 74 h-index	7136 153 g-index
281 all docs	281 docs citations	281 times ranked	33273 citing authors

#	Article	IF	Citations
1	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018, 7, 1535750.	5.5	6,961
2	Age-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and Frailty. Annual Review of Medicine, 2000, 51, 245-270.	5.0	1,066
3	Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Research, 2002, 62, 1832-7.	0.4	768
4	Stromal cells in tumor microenvironment and breast cancer. Cancer and Metastasis Reviews, 2013, 32, 303-315.	2.7	536
5	Efficient mapping of mendelian traits in dogs through genome-wide association. Nature Genetics, 2007, 39, 1321-1328.	9.4	474
6	Osteoprotegerin inhibits prostate cancerâ€"induced osteoclastogenesis and prevents prostate tumor growth in the bone. Journal of Clinical Investigation, 2001, 107, 1235-1244.	3.9	406
7	Effects of Raf Kinase Inhibitor Protein Expression on Suppression of Prostate Cancer Metastasis. Journal of the National Cancer Institute, 2003, 95, 878-889.	3.0	349
8	Skeletal Localization and Neutralization of the SDF-1(CXCL12)/CXCR4 Axis Blocks Prostate Cancer Metastasis and Growth in Osseous Sites In Vivo. Journal of Bone and Mineral Research, 2004, 20, 318-329.	3.1	345
9	Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nature Communications, 2013, 4, 1795.	5.8	342
10	Human ovarian carcinomaâ€"associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. Journal of Clinical Investigation, 2011, 121, 3206-3219.	3.9	305
11	NF-ÎºB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nature Medicine, 2007, 13, 62-69.	15.2	296
12	Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. American Journal of Physiology - Cell Physiology, 2007, 292, C987-C995.	2.1	290
13	Prostate Cancer Cells Promote Osteoblastic Bone Metastases through Wnts. Cancer Research, 2005, 65, 7554-7560.	0.4	277
14	Androgen Receptor: An Overview. Critical Reviews in Eukaryotic Gene Expression, 1995, 5, 97-125.	0.4	260
15	Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. Journal of Cellular Biochemistry, 2004, 91, 718-729.	1.2	251
16	Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene, 2010, 29, 811-821.	2.6	246
17	Interleukin-6 and prostate cancer progression. Cytokine and Growth Factor Reviews, 2001, 12, 33-40.	3.2	236
18	MT1-MMP-Dependent Control of Skeletal Stem Cell Commitment via a Î²1-Integrin/YAP/TAZ Signaling Axis. Developmental Cell, 2013, 25, 402-416.	3.1	219

#	Article	IF	Citations
19	RKIP Sensitizes Prostate and Breast Cancer Cells to Drug-induced Apoptosis. Journal of Biological Chemistry, 2004, 279, 17515-17523.	1.6	203
20	Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate, 2006, 66, 248-256.	1.2	197
21	Polycomb Protein EZH2 Regulates Tumor Invasion via the Transcriptional Repression of the Metastasis Suppressor RKIP in Breast and Prostate Cancer. Cancer Research, 2012, 72, 3091-3104.	0.4	195
22	Evaluation of Prognostic Factors and Sequential Combination Chemotherapy With Doxorubicin for Canine Lymphoma. Journal of Veterinary Internal Medicine, 1993, 7, 289-295.	0.6	192
23	Bone Morphogenetic Protein-6 Promotes Osteoblastic Prostate Cancer Bone Metastases through a Dual Mechanism. Cancer Research, 2005, 65, 8274-8285.	0.4	189
24	Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer and Metastasis Reviews, 2001, 20, 333-349.	2.7	179
25	Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene, 2008, 27, 2243-2248.	2.6	179
26	Snail/Slug binding interactions with YAP/TAZ control skeletal stem cell self-renewal and differentiation. Nature Cell Biology, 2016, 18, 917-929.	4.6	175
27	Bone Turnover Mediates Preferential Localization of Prostate Cancer in the Skeleton. Endocrinology, 2005, 146, 1727-1736.	1.4	174
28	Stromal factors involved in prostate carcinoma metastasis to bone. Cancer, 2003, 97, 739-747.	2.0	168
29	RANKL acts directly on RANKâ€expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate, 2008, 68, 92-104.	1.2	165
30	The Adrenal Androgen Androstenediol Is Present in Prostate Cancer Tissue after Androgen Deprivation Therapy and Activates Mutated Androgen Receptor. Cancer Research, 2004, 64, 765-771.	0.4	164
31	Role of wnts in prostate cancer bone metastases. Journal of Cellular Biochemistry, 2006, 97, 661-672.	1.2	155
32	Cutting Edge: Opposite Effects of IL-1 and IL-2 on the Regulation of IL-17+ T Cell Pool IL-1 Subverts IL-2-Mediated Suppression. Journal of Immunology, 2007, 179, 1423-1426.	0.4	155
33	Monocyte Chemotactic Protein-1 Mediates Prostate Cancerâ€"Induced Bone Resorption. Cancer Research, 2007, 67, 3646-3653.	0.4	154
34	The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochemical Pharmacology, 2004, 68, 1049-1053.	2.0	150
35	Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate, 2001, 47, 212-221.	1.2	149
36	A Glycolytic Mechanism Regulating an Angiogenic Switch in Prostate Cancer. Cancer Research, 2007, 67, 149-159.	0.4	140

#	Article	IF	Citations
37	Polarization of Prostate Cancer-associated Macrophages Is Induced by Milk Fat Globule-EGF Factor 8 (MFG-E8)-mediated Efferocytosis. Journal of Biological Chemistry, 2014, 289, 24560-24572.	1.6	140
38	Vascular Endothelial Growth Factor Contributes to the Prostate Cancer-Induced Osteoblast Differentiation Mediated by Bone Morphogenetic Protein. Cancer Research, 2004, 64, 994-999.	0.4	139
39	HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. Cancer Research, 2017, 77, 74-85.	0.4	137
40	Inhibition of Interleukin-6 with CNTO328, an Anti-Interleukin-6 Monoclonal Antibody, Inhibits Conversion of Androgen-Dependent Prostate Cancer to an Androgen-Independent Phenotype in Orchiectomized Mice. Cancer Research, 2006, 66, 3087-3095.	0.4	136
41	Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype. Journal of Clinical Oncology, 2005, 23, 8232-8241.	0.8	135
42	Cyclooxygenase-2 promotes prostate cancer progression. Prostate, 2002, 53, 232-240.	1.2	134
43	Prostate Cancer Induces Bone Metastasis through Wnt-Induced Bone Morphogenetic Protein-Dependent and Independent Mechanisms. Cancer Research, 2008, 68, 5785-5794.	0.4	131
44	The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate, 2007, 67, 955-967.	1.2	130
45	Dickkopfâ€1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate, 2008, 68, 1396-1404.	1.2	127
46	Inhibition of NFÎºB Activity through Maintenance of IÎºBÎ± Levels Contributes to Dihydrotestosterone-mediated Repression of the Interleukin-6 Promoter. Journal of Biological Chemistry, 1996, 271, 26267-26275.	1.6	126
47	Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. OncoImmunology, 2012, 1, 152-161.	2.1	123
48	Tumor-Induced Pressure in the Bone Microenvironment Causes Osteocytes to Promote the Growth of Prostate Cancer Bone Metastases. Cancer Research, 2015, 75, 2151-2158.	0.4	123
49	Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice. Journal of Clinical Investigation, 2000, 106, 887-895.	3.9	123
50	Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis. Journal of Experimental Medicine, 2019, 216, 2883-2899.	4.2	122
51	Expression of the cytoskeleton linker protein ezrin in human cancers. Clinical and Experimental Metastasis, 2007, 24, 69-78.	1.7	118
52	Type I Collagen Receptor (Î±2Î²1) Signaling Promotes the Growth of Human Prostate Cancer Cells within the Bone. Cancer Research, 2006, 66, 8648-8654.	0.4	116
53	Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Research, 2003, 63, 7883-90.	0.4	116
54	Anabolic Actions of Parathyroid Hormone during Bone Growth Are Dependent on c-fos. Endocrinology, 2002, 143, 4038-4047.	1.4	115

#	Article	IF	Citations
55	CCR2 expression correlates with prostate cancer progression. Journal of Cellular Biochemistry, 2007, 101, 676-685.	1.2	115
56	Metformin targets multiple signaling pathways in cancer. Chinese Journal of Cancer, 2017, 36, 17.	4.9	115
57	Hydrogen Peroxide Activates NFÎºB and the Interleukin-6 Promoter Through NFÎºB-Inducing Kinase. Antioxidants and Redox Signaling, 2001, 3, 493-504.	2.5	112
58	Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate, 2001, 48, 47-53.	1.2	112
59	Type I Collagen Receptor (Î±2Î²1) Signaling Promotes Prostate Cancer Invasion through RhoC GTPase. Neoplasia, 2008, 10, 797-803.	2.3	111
60	Mechanisms of Unexplained Anemia in the Nursing Home. Journal of the American Geriatrics Society, 2004, 52, 423-427.	1.3	108
61	Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone, 2008, 42, 806-818.	1.4	108
62	Dickkopfâ€1 (DKKâ€1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate, 2011, 71, 615-625.	1.2	105
63	Breast cancerâ€derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases. International Journal of Cancer, 2008, 123, 1034-1042.	2.3	104
64	Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. Journal of Clinical Investigation, 2017, 128, 248-266.	3.9	103
65	Ionizing Radiation Induces Prostate Cancer Neuroendocrine Differentiation through Interplay of CREB and ATF2: Implications for Disease Progression. Cancer Research, 2008, 68, 9663-9670.	0.4	100
66	Vascular Endothelial Growth Factor Contributes to Prostate Cancerâ€"Mediated Osteoblastic Activity. Cancer Research, 2005, 65, 10921-10929.	0.4	91
67	Doubleâ€blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer, 2014, 120, 692-701.	2.0	91
68	ERK5 signalling in prostate cancer promotes an invasive phenotype. British Journal of Cancer, 2011, 104, 664-672.	2.9	90
69	Integrin alpha2beta1 (Î±2Î²1) promotes prostate cancer skeletal metastasis. Clinical and Experimental Metastasis, 2013, 30, 569-578.	1.7	88
70	High-Throughput Microfluidic Labyrinth for the Label-free Isolation of Circulating Tumor Cells. Cell Systems, 2017, 5, 295-304.e4.	2.9	88
71	Osteoclast-mediated bone resorption is controlled by a compensatory network of secreted and membrane-tethered metalloproteinases. Science Translational Medicine, 2020, 12, .	5.8	85
72	The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. Journal of Cellular Biochemistry, 2005, 94, 273-278.	1.2	81

#	Article	IF	Citations
73	TUMOR NECROSIS FACTOR-Î± REPRESSES ANDROGEN SENSITIVITY IN THE LNCaP PROSTATE CANCER CELL LINE. Journal of Urology, 2000, 164, 800-805.	0.2	80
74	The use of mature zebrafish (Danio rerio) as a model for human aging and disease. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2004, 138, 335-341.	1.3	80
75	Estrogen Inhibits Phorbol Ester-Induced IÎºBÎ± Transcription and Protein Degradation. Biochemical and Biophysical Research Communications, 1998, 244, 691-695.	1.0	78
76	Raf kinase inhibitor protein: a prostate cancer metastasis suppressor gene. Cancer Letters, 2004, 207, 131-137.	3.2	76
77	Raf kinase inhibitor protein (RKIP) in cancer. Cancer and Metastasis Reviews, 2012, 31, 615-620.	2.7	76
78	Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions. Clinical Cancer Research, 2014, 20, 617-630.	3.2	75
79	An In Vivo Mouse Model for Human Prostate Cancer Metastasis. Neoplasia, 2008, 10, 371-IN4.	2.3	74
80	Exosome-derived microRNAs contribute to prostate cancer chemoresistance. International Journal of Oncology, 2016, 49, 838-846.	1.4	74
81	Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design. Clinical Genitourinary Cancer, 2006, 4, 299-302.	0.9	73
82	The role of Wnts in bone metastases. Cancer and Metastasis Reviews, 2007, 25, 551-558.	2.7	73
83	Notch Pathway Inhibition Using PF-03084014, a Î³-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer. Clinical Cancer Research, 2015, 21, 4619-4629.	3.2	73
84	Wnt3a: functions and implications in cancer. Chinese Journal of Cancer, 2015, 34, 554-62.	4.9	72
85	Characterization of the heat shock response in mature zebrafish (Danio rerio). Experimental Gerontology, 2003, 38, 683-691.	1.2	70
86	Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion. Oncogene, 2019, 38, 4540-4559.	2.6	68
87	Impact of the Mitogen-activated Protein Kinase Pathway on Parathyroid Hormone-related Protein Actions in Osteoblasts. Journal of Biological Chemistry, 2004, 279, 29121-29129.	1.6	65
88	Immunologic aspects of osteoporosis. Developmental and Comparative Immunology, 1997, 21, 487-499.	1.0	63
89	Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion. Osteoporosis International, 2016, 27, 1469-1476.	1.3	63
90	Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chinese Journal of Cancer, 2017, 36, 35.	4.9	63

#	Article	IF	Citations
91	The Bisphosphonate YM529 Inhibits Osteolytic and Osteoblastic Changes and CXCR-4â€"Induced Invasion in Prostate Cancer. Cancer Research, 2005, 65, 8818-8825.	0.4	62
92	PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasionin vitro. International Journal of Cancer, 2007, 121, 724-733.	2.3	60
93	Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocrine-Related Cancer, 2009, 16, 1139-1155.	1.6	59
94	Mangiferin Attenuates Th1/Th2 Cytokine Imbalance in an Ovalbumin-Induced Asthmatic Mouse Model. PLoS ONE, 2014, 9, e100394.	1.1	59
95	Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3î² signaling. Scientific Reports, 2017, 7, 41656.	1.6	58
96	Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clinical and Experimental Metastasis, 2004, 21, 399-408.	1.7	57
97	Development of Human Granulocyte-Macrophage Colony-Stimulating Factor-Transfected Tumor Cell Vaccines for the Treatment of Spontaneous Canine Cancer. Human Gene Therapy, 1998, 9, 1851-1861.	1.4	56
98	Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease. Oncogene, 2016, 35, 366-376.	2.6	56
99	Humoral Hypercalcemia of Malignancy. American Journal of Pathology, 2001, 158, 2219-2228.	1.9	55
100	Trends in early mineralization of murine calvarial osteoblastic cultures: a Raman microscopic study. Journal of Raman Spectroscopy, 2002, 33, 536-543.	1.2	55
101	Metastasis suppressor genes: a role for raf kinase inhibitor protein (RKIP). Anti-Cancer Drugs, 2004, 15, 663-669.	0.7	55
102	Understanding and Targeting Osteoclastic Activity in Prostate Cancer Bone Metastases. Current Molecular Medicine, 2013, 13, 626-639.	0.6	55
103	Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. European Urology, 2018, 74, 741-753.	0.9	54
104	Detection and Isolation of Circulating Tumor Cells in Urologic Cancers: A Review. Neoplasia, 2004, 6, 302-309.	2.3	53
105	The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clinical and Experimental Metastasis, 2004, 21, 381-387.	1.7	52
106	Loss of Raf Kinase Inhibitory Protein Induces Radioresistance in Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 153-160.	0.4	52
107	Prevalence of Prostate Cancer Metastases after Intravenous Inoculation Provides Clues into the Molecular Basis of Dormancy in the Bone Marrow Microenvironment. Neoplasia, 2012, 14, 429-439.	2.3	51
108	Survey of Raf Kinase Inhibitor Protein (RKIP) in Multiple Cancer Types. Critical Reviews in Oncogenesis, 2014, 19, 455-468.	0.2	51

#	Article	IF	Citations
109	Heat stress-induced heat shock protein 70 expression is dependent on ERK activation in zebrafish (Danio rerio) cells. Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2008, 150, 307-314.	0.8	50
110	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Investigational New Drugs, 2011, 29, 1432-1440.	1.2	49
111	Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treatment Reviews, 2014, 40, 730-738.	3.4	48
112	The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs of Today, 2002, 38, 91.	2.4	48
113	Orchiectomy Increases Bone Marrow Interleukin-6 Levels in Mice. Calcified Tissue International, 1998, 62, 219-226.	1.5	46
114	Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor Î²1â€associated osteoblastic changes. Prostate, 2009, 69, 1222-1234.	1.2	45
115	Histotripsy Focal Ablation of Implanted Prostate Tumor in an ACE-1 Canine Cancer Model. Journal of Urology, 2012, 188, 1957-1964.	0.2	45
116	The impact of chronic estrogen deprivation on immunologic parameters in the ovariectomized rhesus monkey (Macaca mulatta) model of menopause. Journal of Reproductive Immunology, 2001, 50, 41-55.	0.8	44
117	Integrative differential expression and gene set enrichment analysis using summary statistics for scRNA-seq studies. Nature Communications, 2020, 11, 1585.	5.8	43
118	In vivo real-time imaging of TGF-?-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer. Prostate, 2004, 59, 360-369.	1.2	42
119	ALDH activity indicates increased tumorigenic cells, but not cancer stem cells, in prostate cancer cell lines. In Vivo, 2011, 25, 69-76.	0.6	42
120	Disseminated Prostate Cancer Cells Can Instruct Hematopoietic Stem and Progenitor Cells to Regulate Bone Phenotype. Molecular Cancer Research, 2012, 10, 282-292.	1.5	41
121	Hematologic and serum biochemical values for zebrafish (Danio rerio). Comparative Medicine, 2003, 53, 37-41.	0.4	41
122	Characterization of C4-2 Prostate Cancer Bone Metastases and Their Response to Castration. Journal of Bone and Mineral Research, 2003, 18, 1882-1888.	3.1	40
123	Mechanisms of Metastatic Tumor Dormancy. Journal of Clinical Medicine, 2013, 2, 136-150.	1.0	40
124	TUMOR NECROSIS FACTOR-?? REPRESSES ANDROGEN SENSITIVITY IN THE LNCaP PROSTATE CANCER CELL LINE. Journal of Urology, 2000, 164, 800-805.	0.2	40
125	Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells. Prostate, 2002, 51, 10-20.	1.2	39
126	p21CIP-1/WAF-1 Induction Is Required to Inhibit Prostate Cancer Growth Elicited by Deficient Expression of the Wnt Inhibitor Dickkopf-1. Cancer Research, 2010, 70, 9916-9926.	0.4	39

#	Article	IF	Citations
127	Correlation of estradiol, parathyroid hormone, interleukin-6, and soluble interleukin-6 receptor during the normal menstrual cycle. Bone, 2000, 26, 79-85.	1.4	38
128	EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. Prostate, 2009, 69, 528-537.	1.2	38
129	Exogenous SPARC Suppresses Proliferation and Migration of Prostate Cancer by Interacting With Integrin Î²1. Prostate, 2013, 73, 1159-1170.	1.2	38
130	A novel canine model for prostate cancer. Prostate, 2013, 73, 952-959.	1.2	38
131	Immune mediators in the tumor microenvironment of prostate cancer. Chinese Journal of Cancer, 2017, 36, 29.	4.9	38
132	Targeting the <scp>N</scp>otch signaling pathway in cancer therapeutics. Thoracic Cancer, 2014, 5, 473-486.	0.8	37
133	Cytotoxic necrotizing factor 1 promotes prostate cancer progression through activating the Cdc42â€"PAK1 axis. Journal of Pathology, 2017, 243, 208-219.	2.1	37
134	Current Studies of Liposome Muramyl Tripeptide (CGP 19835A Lipid) Therapy for Metastasis in Spontaneous Tumors: A Progress Review*. Journal of Drug Targeting, 1994, 2, 391-396.	2.1	35
135	Annexin 2â€"CXCL12 Interactions Regulate Metastatic Cell Targeting and Growth in the Bone Marrow. Molecular Cancer Research, 2015, 13, 197-207.	1.5	35
136	Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Research and Treatment, 2016, 159, 87-95.	1.1	35
137	Immune-mediated disease as a risk factor for canine lymphoma. Cancer, 1992, 70, 2334-2337.	2.0	34
138	Fibulin-3 promotes muscle-invasive bladder cancer. Oncogene, 2017, 36, 5243-5251.	2.6	34
139	Carnitine and Dehydroepiandrosterone Sulfate Induce Protein Synthesis in Porcine Primary Osteoblast-Like Cells. Calcified Tissue International, 1999, 64, 527-533.	1.5	32
140	Development of a brain metastatic canine prostate cancer cell line. Prostate, 2011, 71, 1251-1263.	1.2	32
141	Fyn Is Downstream of the HGF/MET Signaling Axis and Affects Cellular Shape and Tropism in PC3 Cells. Clinical Cancer Research, 2011, 17, 3112-3122.	3.2	32
142	Mindful exercise versus non-mindful exercise for schizophrenia: A systematic review and meta-analysis of randomized controlled trials. Complementary Therapies in Clinical Practice, 2018, 32, 17-24.	0.7	32
143	Alzheimerâ€™s AÎ² vaccination of rhesus monkeys (Macaca mulatta). Mechanisms of Ageing and Development, 2004, 125, 149-151.	2.2	31
144	Transcriptional Regulation of RKIP Expression by Androgen in Prostate Cells. Cellular Physiology and Biochemistry, 2012, 30, 1340-1350.	1.1	31

#	Article	IF	Citations
145	Osteocytes Serve as a Progenitor Cell of Osteosarcoma. Journal of Cellular Biochemistry, 2014, 115, 1420-1429.	1.2	31
146	In vivo visualization of aging-associated gene transcription: evidence for free radical theory of aging. Experimental Gerontology, 2004, 39, 239-247.	1.2	30
147	Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer and Prostatic Diseases, 2005, 8, 253-259.	2.0	30
148	Skp2 is associated with paclitaxel resistance in prostate cancer cells. Oncology Reports, 2016, 36, 559-566.	1.2	30
149	Expression of PGK1 by Prostate Cancer Cells Induces Bone Formation. Molecular Cancer Research, 2009, 7, 1595-1604.	1.5	29
150	Wnt and Wnt inhibitors in bone metastasis. BoneKEy Reports, 2012, 1, 101.	2.7	29
151	Activation of the Wnt Pathway through AR79, a GSK3Î² Inhibitor, Promotes Prostate Cancer Growth in Soft Tissue and Bone. Molecular Cancer Research, 2013, 11, 1597-1610.	1.5	29
152	Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis. Journal of Cancer, 2016, 7, 192-199.	1.2	29
153	Abituzumab Targeting of Î±V-Class Integrins Inhibits Prostate Cancer Progression. Molecular Cancer Research, 2017, 15, 875-883.	1.5	29
154	Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcified Tissue International, 2018, 102, 152-162.	1.5	29
155	Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1999-2012.	1.2	29
156	Notch3 promotes prostate cancer-induced bone lesion development via MMP-3. Oncogene, 2020, 39, 204-218.	2.6	29
157	OPG, RANKL, and RANK in Cancer Metastasis: Expression and Regulation. Cancer Treatment and Research, 2004, 118, 149-172.	0.2	28
158	Ethanol activates NFÎºB DNA binding and p56lck protein tyrosine kinase in human osteoblast-like cells. Bone, 2001, 28, 167-173.	1.4	26
159	Separation of retinoid-induced epidermal and dermal thickening from skin irritation. Archives of Dermatological Research, 2003, 295, 255-262.	1.1	26
160	The PCa Tumor Microenvironment. Cancer Microenvironment, 2011, 4, 283-297.	3.1	26
161	Cellular, transcriptomic and isoform heterogeneity of breast cancer cell line revealed by full-length single-cell RNA sequencing. Computational and Structural Biotechnology Journal, 2020, 18, 676-685.	1.9	26
162	Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. Oncotarget, 2018, 9, 16185-16196.	0.8	26

#	Article	IF	Citations
163	RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. Prostate, 2008, 68, 820-829.	1.2	25
164	Prostate Cancer and Parasitism of the Bone Hematopoietic Stem Cell Niche. Critical Reviews in Eukaryotic Gene Expression, 2012, 22, 131-148.	0.4	25
165	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia, 2016, 18, 1-9.	2.3	25
166	Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells. Biomedicines, 2020, 8, 253.	1.4	25
167	Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 as a Regulator of Docetaxel Resistance in Prostate Cancer Cells. Molecular Cancer Research, 2020, 18, 1290-1301.	1.5	25
168	Alzheimer AÎ² Vaccination of Rhesus Monkeys (Macaca Mulatta). Alzheimer Disease and Associated Disorders, 2004, 18, 44-46.	0.6	24
169	CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer. Prostate, 2010, 70, 48-60.	1.2	24
170	SOD3 acts as a tumor suppressor in PC-3 prostate cancer cells via hydrogen peroxide accumulation. Anticancer Research, 2014, 34, 2821-31.	0.5	23
171	An integrative model of prostate cancer interaction with the bone microenvironment. Mathematical Biosciences, 2017, 294, 1-14.	0.9	22
172	SNV identification from single-cell RNA sequencing data. Human Molecular Genetics, 2019, 28, 3569-3583.	1.4	22
173	Change in Markers of Bone Metabolism with Chemotherapy for Advanced Prostate Cancer: Interleukin-6 Response Is a Potential Early Indicator of Response to Therapy. Journal of Interferon and Cytokine Research, 2009, 29, 105-111.	0.5	21
174	Reversal of Chemotherapy-Induced Leukopenia Using Granulocyte Macrophage Colony-Stimulating Factor Promotes Bone Metastasis That Can Be Blocked with Osteoclast Inhibitors. Cancer Research, 2010, 70, 5014-5023.	0.4	21
175	Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells. International Journal of Urology, 2006, 13, 593-600.	0.5	20
176	Downâ€regulation of calcium/calmodulinâ€dependent protein kinase kinase 2 by androgen deprivation induces castrationâ€resistant prostate cancer. Prostate, 2012, 72, 1789-1801.	1.2	20
177	Cytotoxic necrotizing factor 1 promotes bladder cancer angiogenesis through activating RhoC. FASEB Journal, 2020, 34, 7927-7940.	0.2	20
178	Neurotrophic role of interleukin-6 and soluble interleukin-6 receptors in N1E-115 neuroblastoma cells. Journal of Neuroimmunology, 2000, 102, 8-16.	1.1	19
179	Long-term exposure of tumor necrosis factor ? causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. Prostate, 2001, 46, 319-326.	1.2	19
180	Review of Animal Models of Prostate Cancer Bone Metastasis. Veterinary Sciences, 2014, 1, 16-39.	0.6	19

#	Article	IF	Citations
181	A surgical orthotopic approach for studying the invasive progression of human bladder cancer. Nature Protocols, 2019, 14, 738-755.	5.5	19
182	Correlation of serum L-carnitine and dehydro-epiandrosterone sulphate levels with age and sex in healthy adults. Age and Ageing, 1999, 28, 211-216.	0.7	18
183	New trends in the treatment of bone metastasis. Journal of Cellular Biochemistry, 2007, 102, 1095-1102.	1.2	18
184	Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of Î²-catenin activation of the DKK1 promoter in prostate cancer. Oncogene, 2014, 33, 2464-2477.	2.6	18
185	Osteoprotegerin Abrogates Chronic Alcohol Ingestion-Induced Bone Loss in Mice. Journal of Bone and Mineral Research, 2002, 17, 1256-1263.	3.1	17
186	Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer. Prostate, 2015, 75, 292-302.	1.2	17
187	Knockdown of Notch1 inhibits nasopharyngeal carcinoma cell growth and metastasis via downregulation of CCL2, CXCL16, and uPA. Molecular Carcinogenesis, 2019, 58, 1886-1896.	1.3	15
188	An infection-induced RhoB-Beclin 1-Hsp90 complex enhances clearance of uropathogenic Escherichia coli. Nature Communications, 2021, 12, 2587.	5.8	14
189	A bioluminescent orthotopic mouse model of human osteosarcoma that allows sensitive and rapid evaluation of new therapeutic agents In vivo. In Vivo, 2009, 23, 661-8.	0.6	14
190	Why should we still care about oncogenes?. Molecular Cancer Therapeutics, 2007, 6, 418-427.	1.9	13
191	IgV somatic mutation of human antiâ€“SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity. JCI Insight, 2021, 6, .	2.3	13
192	Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer. Critical Reviews in Oncogenesis, 2015, 20, 407-417.	0.2	13
193	Tumor microenvironment promotes prostate cancer cell dissemination via the Akt/mTOR pathway. Oncotarget, 2018, 9, 9206-9218.	0.8	13
194	Ovariectomy does not induce osteopenia through interleukin-6 in rhesus monkeys (Macaca mulatta). Bone, 2000, 26, 55-62.	1.4	12
195	Simultaneous Single Cell Gene Expression and EGFR Mutation Analysis of Circulating Tumor Cells Reveals Distinct Phenotypes in NSCLC. Advanced Biology, 2020, 4, e2000110.	3.0	12
196	Cigarette smoke-associated inflammation impairs bone remodeling through NFÎºB activation. Journal of Translational Medicine, 2021, 19, 163.	1.8	12
197	<title>Early mineralization of normal and pathologic calvaria as revealed by Raman spectroscopy</title>. , 2002, , .		11
198	Micro/Nanostructures and Mechanical Properties of Trabecular Bone in Ovariectomized Rats. International Journal of Endocrinology, 2015, 2015, 1-10.	0.6	11

#	Article	IF	Citations
199	Translational progress on tumor biomarkers. Thoracic Cancer, 2015, 6, 665-671.	0.8	11
200	Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance. Molecular Cancer Research, 2017, 15, 457-466.	1.5	10
201	IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker. Oncotarget, 2016, 7, 68140-68150.	0.8	10
202	A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors. Journal of Hepatocellular Carcinoma, 2014, 1, 1.	1.8	9
203	Repression of cell proliferation and androgen receptor activity in prostate cancer cells by 2'-hydroxyflavanone. Anticancer Research, 2013, 33, 4453-61.	0.5	8
204	Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution. Biology of Blood and Marrow Transplantation, 2006, 12, 100-106.	2.0	7
205	Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer. Cancer Letters, 2018, 436, 96-108.	3.2	7
206	The Use of Mature Zebrafish (Danio rerio) as a Model for Human Aging and Disease. , 2018, , 351-359.		7
207	SPDEF: a molecular switch for E-cadherin expression that promotes prostate cancer metastasis. Asian Journal of Andrology, 2013, 15, 584-585.	0.8	7
208	Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2012, 30, 265-265.	0.8	7
209	Photoacoustic spectral analysis at ultraviolet wavelengths for characterizing the Gleason grades of prostate cancer. Optics Letters, 2020, 45, 6042.	1.7	7
210	Role of Raf Kinase Inhibitor Protein in Pathophysiology of Prostate Cancer. Forum on Immunopathological Diseases and Therapeutics, 2011, 2, 89-94.	0.1	7
211	Raman microscopy of bladder cancer cells expressing green fluorescent protein. Journal of Biomedical Optics, 2016, 21, 115001.	1.4	6
212	Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer. BMC Cancer, 2021, 21, 1316.	1.1	6
213	Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 332-339.e2.	0.9	5
214	Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells. Anticancer Research, 2018, 38, 2045-2055.	0.5	5
215	Prostate cancer tends to metastasize in the bone-mimicking microenvironment via activating NF-kB signaling. Journal of Biomedical Research, 2018, 32, 343.	0.7	5
216	Zebrafish, Killifish, Neither Fish, Both Fish?. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2004, 59, B873-B875.	1.7	4

#	Article	IF	Citations
217	Macrofluidic recirculating model of skeletal metastasis. Scientific Reports, 2019, 9, 14979.	1.6	4
218	Targeted Notch1 inhibition with a Notch1 antibody, OMPâ€A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression. Journal of Cellular Biochemistry, 2019, 120, 16946-16955.	1.2	4
219	Extracellular Vesicles and Bone-Associated Cancer. Current Osteoporosis Reports, 2021, 19, 223-229.	1.5	4
220	Raman spectroscopy of bone metastasis. Proceedings of SPIE, 2012, , .	0.8	3
221	Analysis of Integrin Alpha2Beta1 (Î±2Î²1) Expression as a Biomarker of Skeletal Metastasis. Biomarkers in Disease, 2017, , 487-506.	0.0	3
222	The comparative biology of skeletal metastasis. Veterinary and Comparative Oncology, 2003, 1, 131-139.	0.8	2
223	Providing prostate cancer survivorship care in Japan: Implications from the USA care model. International Journal of Urology, 2016, 23, 906-915.	0.5	2
224	â€˜Educatedâ€™ Osteoblasts Reduce Osteoclastogenesis in a Bone-Tumor Mimetic Microenvironment. Cancers, 2021, 13, 263.	1.7	2
225	Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. , 2001, 48, 47.		2
226	Detection and Isolation of Human Disseminated Tumor Cells in the Murine Bone Marrow Stem Cell Niche. Methods in Molecular Biology, 2013, 1035, 207-215.	0.4	2
227	Prostate cancer cells metastasize to the hematopoietic stem cell niche in bone. Asian Journal of Andrology, 2011, 13, 622-623.	0.8	2
228	Abstract 3794: Inhibition of prostate cancer bone metastases by the dickkopf-1 neutralizing antibody BHQ880. , 2012, , .		2
229	Pheno-SELEX: Engineering Anti-Metastatic Aptamers through Targeting the Invasive Phenotype Using Systemic Evolution of Ligands by Exponential Enrichment. Bioengineering, 2021, 8, 212.	1.6	2
230	Differential immune landscapes in appendicular versus axial skeleton. PLoS ONE, 2022, 17, e0267642.	1.1	2
231	Integrated Workflow for the Label-Free Isolation and Genomic Analysis of Single Circulating Tumor Cells in Pancreatic Cancer. International Journal of Molecular Sciences, 2022, 23, 7852.	1.8	2
232	Raman imaging as a probe of chemical and biomechanical properties of bone tissue. , 2000, 3918, 2.		1
233	The Use of Mature Zebrafish (Danio rerio) as a Model for Human Aging and Disease. , 2006, , 309-316.		1
234	Radium-223: a new treatment option for bone-metastatic CRPC. Nature Reviews Urology, 2013, 10, 630-631.	1.9	1

#	Article	IF	Citations
235	Abstract 2851: Cabozantinib (XL184) inhibits prostate tumor growth and bone lesion development. , 2012, , .		1
236	Abstract 1: Interaction of prostate cancer cells with tumor microenvironment promotes EMT and DTCs activation. , 2014, , .		1
237	Abstract 841: CCL2 and interleukin-6 regulate EMT-mediated chemo-resistance in prostate cancer. , 2012, , .		1
238	A Bioreactor for 3D In Vitro Modeling of the Mechanical Stimulation of Osteocytes. Frontiers in Bioengineering and Biotechnology, 2022, 10, 797542.	2.0	1
239	20 Immunohistochemical expression of raf kinase inhibitor protein in prostate carcinoma. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2002, , 471-479.	0.0	0
240	Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. , 2002, , 197-213.		0
241	Biology and Therapeutic Basis of Prostate Cancer Bone Metastasis. , 2007, , 175-191.		0
242	381 ABERRANT EXTRACELLULAR SIGNAL-REGULATED PROTEIN KINASE 5 (ERK5) SIGNALLING PROMOTES CELLULAR MOTILITY AND INVASION IN PROSTATE CARCINOGENESIS. Journal of Urology, 2010, 183, .	0.2	0
243	794 HISTOTRIPSY FOCAL ABLATION OF IMPLANTED PROSTATE TUMOR IN AN ACE-1 CANINE CANCER MODEL. Journal of Urology, 2012, 187, .	0.2	0
244	Multiple Roles of Osteocytes in Bone-Associated Cancers. , 2020, , 219-224.		0
245	Effects of Analgesics on Tumor Growth in Mouse Models of Prostate Cancer Bone Metastasis. Journal of the American Association for Laboratory Animal Science, 2021, 60, 341-348.	0.6	0
246	Pathophysiology of Prostate Cancer Bone Metastasis. , 2010, , 245-254.		0
247	Abstract LB-374: IGFBP-6, a novel prognostic biomarker in nasopharyngeal carcinoma (NPC) patients. , 2011, , .		0
248	Abstract 166: MicroRNA profiling analysis identify new signature of tumor-promoting M2-type macrophages. , 2011, , .		0
249	Abstract 944: Down-regulation of CAMKK2 by androgen deprivation induces castration-resistant prostate cancer. , 2012, , .		0
250	Evaluation of aÂnovel irreversible pan-HER inhibitor in bladder cancer models.. Journal of Clinical Oncology, 2013, 31, 253-253.	0.8	0
251	Abstract 3945: IKK-Epsilon, a novel factor identified by proteomics, contributes to prostate cancer cell-induced osteoclast activityin vitro.. , 2013, , .		0
252	Extracellular vesicle-mediated reversal of taxane resistance and the malignant phenotype in prostate cancer.. Journal of Clinical Oncology, 2014, 32, e16028-e16028.	0.8	0

#	ARTICLE	IF	CITATIONS
253	Abstract 617: Repression of cell proliferation and androgen receptor activity by 2â€™-hydroxyflavanone in prostate cancer cells. , 2014, , .		0
254	Abstract 772: CCL2 regulates EMT-mediated chemo-resistance in prostate cancer. , 2014, , .		0
255	Abstract 3198: Extract from Scutellaria baicalensis Georgi inhibits prostate cancer growth in bone. , 2014, , .		0
256	Analysis of Integrin Alpha2Beta1 (Î±2Î²1) Expression as a Biomarker of Skeletal Metastasis. Exposure and Health, 2016, , 1-20.	2.8	0
257	Abstract 965: Exosome-derived microRNAs contributes to prostate cancer chemoresistance. , 2016, , .		0
258	Abstract 1567: Prostate cancer-derived exosomes alter the metabolic microenvironment of bone marrow pre-metastatic niche through PKM2 to promote bone metastasis. , 2016, , .		0
259	Abstract 3307: Label-free high throughput microfluidic device for the isolation and single cell multiplex gene expression analysis of circulating tumor cells from breast cancer patients. , 2016, , .		0
260	Abstract 692: Identifying genes that regulate bladder cancer progression and invasion. , 2016, , .		0
261	Photoacoustic physio-chemical analysis for prostate cancer diagnosis (Conference Presentation). , 2017, , .		0
262	Abstract 85: Establishment of cabazitaxel-resistant prostate cancer cell lines. , 2017, , .		0
263	Abstract 1462: Exosome-derived miR-429 contributes to prostate cancer chemoresistance. , 2017, , .		0
264	Abstract 4939: Activation of GSK3Î²/Î²-catenin pathway promotes organ-specific metastasis in prostate cancer. , 2017, , .		0
265	Abstract 5896: Downregulation of calcium-sensing receptor enhances MET-mediated prostate cancer chemosensitivity. , 2018, , .		0
266	Abstract 996: Host-derived MCP-1 dictates prostate cancer skeletal metastasis in vivo. , 2018, , .		0
267	Abstract 2784: Driver genes network promotes mesenchymal to epithelial transition and organ-specific metastasis. , 2019, , .		0